On September 18, 2018, negotiations closed on what may be the final draft of the “Political Declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases.” The Declaration addresses the measures UN… Continue Reading
On Monday morning, 10 September 2018, Knowledge Ecology International (KEI) delivered the following oral statement at the World Health Organization’s (WHO) Informal Discussion of the Roadmap Report on Access to Medicines and Vaccines 2019–2023. The morning session provided UN agencies,… Continue Reading
On August 20, 2018, KEI filed comments in response to the US Federal Trade Commission’s hearings and public comment process to address, “Competition and Consumer Protection in the 21st Century.” The goal of the process is to examine, “whether broad-based… Continue Reading
On 12 June 2018 and 14 June 2018, the World Trade Organization (WTO) conducted a Trade Policy Review of Colombia. All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place… Continue Reading
On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
USTR has provided some details of the new trade agreement with Mexico, here. As usual, the agreement seems to favor drug companies and holders of copyrights, although few of the details are known. Among the specifics revealed are a proposed… Continue Reading
On August 20, 2018, KEI and T1International filed comments to the NIH regarding the prospective grant of an exclusive license to Inversago Pharma, a firm headquartered in Canada. According to the Federal Register notice 83 FR 38707, the NIH exclusive… Continue Reading
Below are the comments filed by Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) regarding a prospective grant of an exclusive license of NIH-owned patents to the California-based company Midissia Therapeutics. The prospective exclusive license is… Continue Reading
UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to… Continue Reading
The following is a question for the record from Senator Sherrod Brown, and a response from Alex Azar, in connection with Azar’s confirmation hearing. Questions for the Record January 9, 2018 Hearing to Consider the Nomination of Alex Azar to… Continue Reading